INSTRUCTIONS FOR USE: Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

SCOPE: Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).
PLAN PRODUCT AND BENEFIT APPLICATION

☒ Commercial ☒ Medicaid/OHP* ☐ Medicare**

*Medicaid/OHP Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

**Medicare Members

This Company policy may be applied to Medicare Plan members only when directed by a separate Medicare policy. Note that investigational services are considered “not medically necessary” for Medicare members.

COVERAGE CRITERIA

I. Mesenchymal stem cell therapy (e.g., Regenexx, Stravix®) is considered investigational and not covered for all orthopedic applications. This includes but is not limited to allogeneic or autologous stem cells harvested bone marrow, adipose tissue, peripheral blood, synovial or amniotic fluid.

II. Allograft bone products containing viable stem cells, including but not limited to demineralized bone matrix (DBM) with stem cells (e.g., BIO4®, OSTEOCEL® Plus, OSTEOCEL® Pro, OsteoVive™, Trinity Evolution®, Trinity ELITE®, VIA® Form, VIA® Graft, ViviGen®) are considered investigational and not covered for all orthopedic applications.

Link to Evidence Summary

POLICY CROSS REFERENCES

- Stem Cell Transplantation (All Lines of Business Except Medicare)
- Prolotherapy

The full Company portfolio of current Medical Policies is available online and can be accessed here.

POLICY GUIDELINES

BACKGROUND
Stem cells have the potential to differentiate into the types of cells needed to many different types of tissues. Specifically, mesenchymal stem cells (MSCs) are stem cells that have the ability to differentiate into tissues important for repair of orthopedic injuries, including bone, cartilage, tendon and fat. When signaled to form bone, MSCs differentiate into osteoprogenitor cells and then into bone-forming osteoblast cells. However, like all stem cells, MSCs require requires special microenvironments or conditions to promote their differentiation, such as a particular layer of tissue for cell adherence or specific signals from surrounding cells.

Stem cells used for treatment of various orthopedic indications can be harvested from a variety of tissues, including but not limited to bone marrow, adipose tissue, peripheral blood, synovial or amniotic fluid. Most patients are treated with their own stem cells (autologous stem cells) but cells obtained from unrelated donors (allogeneic stem cells) may also be used. Use of allogeneic stem cells avoids the need for harvesting and processing cells from each patient but increases the risk of an immunological reaction that could destroy native cells or cause tissue rejection.

After harvesting of cells from selected tissue, the cells may either be directly injected into affected tissues, including but not limited to joints or spinal discs. The cells may be injected alone or in combination with materials such as hyaluronic acid (HA) that increase joint lubrication or fibrin glue that promotes localized adherence of the cells to damaged joint. Some protocols involve culturing of stem cells prior to injection to increase the number of cells available for injection. However, this may reduce the pluripotency of the cells, making it less likely for them to mature into the desired cell type.

In addition, once MSCs are cultured, they can be mixed with biomaterials, including but not limited to demineralized bone matrix (DBM) to hold the cells in suspension and provide a matrix for filling defects. MSCs can also be seeded on scaffolds made of biomaterials. These types of products are referred to as allograft bone products or cell-based bone graft substitutes.

There are a number of stem-cell containing products that are available to orthopedic applications. Some of examples of these include:

- **Mesenchymal stem cell (MSC) therapy:**
  - **Regenexx® Stem Cell (Regenexx)**: This procedure uses autologous MSCs from bone marrow concentrate, injected using image guidance, to treat defects/injuries of the knee, hip, shoulder spine, elbow, hand/wrist, and foot-ankle.
  - **Stravix® (Osiris Therapeutics, Inc.)**: This product is cryopreserved human placental tissue composed of umbilical amnion and Wharton's jelly that contain MSCs. It is designed to be used as a surgical covering or wrap for various procedures (e.g., tendon repair, Achilles tendon rupture, bunionectomy, hallux rigidus correction, foot amputations, fibromatosis, and arthrodesis).

- **Allograft bone products containing viable stem cells:**
  - **BIO® (Osiris Therapeutics, Inc.)**: This product is referred to as a viable bone matrix containing MSCs to be implanted surgically for orthopedic procedures on the shoulder, elbow, hand/wrist, hip, pelvis, femur, tibia/fibula, or foot/ankle.
  - **map3® (RTI Surgical)**: This product is currently being researched as a cellular allogeneic bone graft composed of cortical cancellous bone, demineralized bone matrix (DBM), and cryogenically preserved viable MSCs.
- **Osteocel® Plus and Osteocel® Pro (Nuvasive®)**: These bone grafts contain allogeneic MSCs and are marketed as bone graft substitutes for use in spinal surgery.

- **OsteoVive™ (Xtant Medical)**: This product is a viable cell allograft that contains MSCs derived from the vertebral body region as well as a demineralized bone component. This product is intended for use in bone remodeling.

- **Trinity Evolution® and Trinity ELITE® (Orthofix®)**: These cancellous bone allografts contain viable adult MSCs and are intended for the treatment of musculoskeletal defects.

- **VIA® Form and VIA® Graft (Vivex Biomedical)**: This is a family of products referred to as “cellular bone matrices” which are viable allogeneic bone allografts with MSC and bone components. These products are intended for use in bone remodeling in a number of applications including spine, upper extremity, foot/ankle, oral/maxillofacial and orthopedic oncology.

- **ViviGen® (DePuy)**: This product is a cellular bone matrix is comprised of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen® is intended for repair or reconstruction of musculoskeletal defects.

### REGULATORY STATUS

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

### CLINICAL EVIDENCE AND LITERATURE REVIEW

#### EVIDENCE REVIEW

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of MSC therapy and allograft bone products containing viable stem cells as treatments for all orthopedic indications. Below is a summary of the available evidence identified through November 2022.

**Mesenchymal Stem Cell (MSC) Therapy**

Due to the volume of literature on MSC therapy as a treatment for a wide variety of conditions, the evidence review is focused on recent systematic reviews. The use of MSC therapy has been recently evaluated by systematic reviews for the following orthopedic indications:

- **Bone healing (non-union or delayed union)**
- **Chondral defects (e.g., ankle, elbow, hip, knee, leg)**
- **Osteoarthritis and Other Degenerative Conditions**:
  - **Osteoarthritis of the ankle**
  - **Osteoarthritis of the carpmotetacarpal joint**
  - **Osteoarthritis of the hip**
  - **Osteoarthritis of the knee**
Osteoarthritis of the shoulder
Osteonecrosis of the knee
Osteonecrosis of the hip
Rheumatoid arthritis of the knee

• Osteochondral lesions of the:
  - knee
  - talus

• Osteochondritis dissecans of the knee

• Other knee indications (e.g., pain from anterior cruciate ligament or meniscus repair, knee cartilage defects, meniscal tears)

• Spinal disc disorders (e.g., lumbar disc disease)

• Tendinopathies:
  - Achilles tendinopathy or tendinosis
  - Lateral epicondylitis
  - Patellar tendinopathy
  - Rotator cuff injury

Systematic reviews were heterogeneous in the methods used to examine primary studies evaluating stem cell therapy, and several concluded the methods of the studies that they reviewed were too heterogeneous for meaningful conclusions. Many reviews included or focused entirely on nonrandomized studies, and many included more than one indication. Reviews that did include RCTs reported that the majority of trials were not blinded, and that randomization methods were questionable. However, in general, the reviews reported differences in treatment protocols related to number of stem cells injected, use of autologous versus allogeneic stem cells, use of freshly isolated versus cultured stem cells, and use of stem cells from varying sources (e.g., bone marrow, adipose tissue, or peripheral blood). Reviews published on the same indication often included studies with patient cohorts of varied stages/severity of disease. All reviews mentioned the need for larger, better-quality studies with longer-term follow-up. The majority of recent reviews were unable to draw definitive conclusions regarding the efficacy of stem therapy as a treatment for any indication.

Overall, the body of evidence for any given indication suffers from one or more of the following limitations:

• extremely limited number of randomized controlled trials (RCTs) reporting outcomes for any given indication
• primary studies, including very small numbers of RCTs, were of low- to very-low quality of due to methodological limitations including:
  - small sample size (under 100 patients)
  - insufficient statistical power or lack of a power analysis
  - lack of or incomplete blinding
  - high rate of attrition
  - primary outcomes reported consisted mostly of subjective, patient-reported outcomes
  - differences in the surgeries and co-interventions that accompanied stem cell therapy
  - insufficient statistical analysis of differences between groups
  - inadequate follow-up
  - heterogeneity of:
    - comparator treatment
• primary outcomes reported
  • evaluation of stem cell therapy as a stand-alone treatment or as an adjunct to a variety of treatments
  • conflicting or no evidence of short-term improvements in pain and/or function (first few months following treatment) when alternate treatments
  • no evidence on long-term outcomes, including function or pain outcomes

Allograft Bone Products Containing Viable Stem Cells

No systematic reviews or randomized controlled trials (RCTs) were identified that evaluated the efficacy of allograft bone products containing viable stem cells for any orthopedic indication. Below is a summary of nonrandomized studies, grouped by product.

OsteoCel and OsteoCel Plus (Nuvasive®)

Only one comparative study was identified that compared Osteocel to standard allograft for use in anterior cervical discectomy and fusion procedures. This was a retrospective study (n=114) that reported that radiologic fusion rates at 12-months post-procedure were not significantly different between treatment groups.

Uncontrolled studies have been published that evaluated the use of Osteocel or Osteocel Plus in different procedures, including:

• lumbar spinal fusion
• anterior cervical discectomy and fusion
• minimally invasive instrumented transforaminal lumbar interbody fusion (MITLIF)
• extreme lateral interbody fusion (XLIF)
• foot and ankle fusions

However, the majority of these studies were small in sample size (52 patients or less) and reported short-term follow-up (5-12 months). In addition, half of these studies were retrospective in study design.

ViviGen® (DePuy)

One small (n=21) retrospective case series reported on the use of ViviGen during cervical spinal fusions. This series included a heterogeneous patient population, as patients included those who either underwent either three- or four-level anterior cervical discectomy and fusion, anterior cervical corpectomy and fusion, or posterior cervical fusion. In addition, only six-month follow up was reported.

map3® Cellular Allogeneic Bone Graft (RTI Surgical)

One small retrospective chart review of 41 patients treated via anterior lumbar interbody fusion (ALIF) with either map3® or recombinant human BMP-2 (rhBMP-2) growth factor reported one-year outcomes. Both of these treatments were evaluated as potential alternatives to conventional iliac crest autograft. The overall fusion rate was 91% and was similar between groups. Improvements in ODI and VAS were observed among all patients with no significant difference between groups. There was no significant difference in terms of changes to disc height and lordosis between groups.
**Trinity Evolution® and Trinity ELITE® (Orthofix®)**

Only one comparative study was identified that compared the Trinity Evolution® to standard allograft for use in patients undergoing single-level anterior cervical discectomy and fusion for symptomatic cervical degenerative disc disease. This was a small study of 31 patients who underwent the procedure using the Trinity bone allograft and the comparator group was historical matched controls. Self-reported pain and function outcomes, as well as fusion rates, were at 12-months post-procedure. Due to the small number of patients, additional larger studies are needed to determine the efficacy of the product.

One small (n=40) uncontrolled study, published by the same authors, evaluated the Trinity Evolution® for use in patients undergoing two-level anterior cervical discectomy and fusion. At 12-month follow-up, this study reported improved self-reported pain and function outcomes compared to baseline and high rates of fusion. A lack of a comparator treatment makes the benefit of this product difficult to assess.

**Evidence Summary for Allograft Bone Products Containing Viable Stem Cells**

Overall, there is a paucity of studies evaluating the efficacy of allograft bone products containing viable stem cells. The overall body of evidence for these products consists mainly of small case series or poorly designed comparative studies. The available studies report relatively short follow-up (six months to two years) and focus primarily on self-reported measures of function and pain. Larger, well-designed comparative studies, preferably randomized trials, reporting longer-term follow-up are required in order to determine if the use of these products is as effective as conventional autografts or allograft products that do not contain stem cells, such as those containing conventional demineralized bone matrix.

**CLINICAL PRACTICE GUIDELINES**

**Department of Veterans Affairs (VA)/Department of Defense (DoD)**

In 2020, the VA/DoD published an evidence-based clinical practice guideline for the non-surgical management of hip and knee osteoarthritis. Investigators issued a “weak recommendation” against stem cell injections for the treatment of osteoarthritis of the knee.

**American Society of Interventional Pain Physicians (ASIPP)**

In 2019, the ASIPP published an evidence-based clinical practice guideline for the responsible, safe, and effective use of biologic therapy in the lumbar spine. Recommendations were graded based on Agency for Healthcare Research and Quality (AHRQ) practice. The guideline notes that MSC and platelet-rich plasma (PRP) injections are the mainstays of regenerative medicine for the lumbar spine. In their review of the evidence, the expert panel identified one high-quality RCT, multiple moderate-quality observational studies, a single-arm meta-analysis, and two systematic reviews regarding MSC therapy. With a qualitative modified approach to the grading of level of evidence, the expert was assessed as Level III (on a scale of Level I through V). Level III evidence is fair: evidence obtained from at least one relevant high quality nonrandomized trial or observational study with multiple moderate or low quality observational studies.

**American Academy of Orthopaedic Surgeons (AAOS)**
The AAOS published evidence-based clinical practice guidelines on the management of osteoarthritis of the hip (2017) and the knee (2021). The association conducted evidence reviews of stem cell therapy versus other comparators for these indications, but did not identify enough high-quality evidence to formally address the treatment in their recommendations.

EVIDENCE SUMMARY

There is insufficient evidence that the use of stem therapy, whether used alone or in conjunction with other biomaterials such as allograft bone product, is effective or consistently improves health outcomes for any orthopedic indication, including but not limited to degenerative and non-degenerative conditions of the hips or knees, spinal disc disorders, and tendinopathies. Interpreting results and drawing conclusions about treatment efficacy is difficult due to heterogeneity in stem cell therapy treatment protocol, including variability in the number of stem cells injected, use of freshly isolated versus cultured stem cells, use of additional biomaterial, and use of stem cells from varying sources (e.g., bone marrow, adipose tissue, or peripheral blood). This limitation is consistently reported for the use of stem cell therapy for all orthopedic indications. Other major limitations of stem cell therapy observed across all indications include a lack of large, well-designed randomized controlled trials, and inconsistency in terms of whether or not stem cell therapy has a beneficial long-term effect. In addition, no clinical practice guidelines were identified that support the use of stem cell therapy as a treatment for any orthopedic indication.

BILLING GUIDELINES AND CODING

<table>
<thead>
<tr>
<th>CODES*</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td></td>
</tr>
<tr>
<td>0565T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation</td>
</tr>
<tr>
<td>0566T</td>
<td>Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral</td>
</tr>
<tr>
<td>0717T</td>
<td>Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs</td>
</tr>
<tr>
<td>0718T</td>
<td>Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral</td>
</tr>
<tr>
<td>20939</td>
<td>Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision</td>
</tr>
<tr>
<td>20999</td>
<td>Unlisted procedure, musculoskeletal system, general</td>
</tr>
<tr>
<td>29999</td>
<td>Unlisted procedure, arthroscopy</td>
</tr>
<tr>
<td>38205</td>
<td>Blood derived hematopoietic progenitor cell harvesting for transplantation, per collection allogeneic</td>
</tr>
<tr>
<td>38206</td>
<td>Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous</td>
</tr>
</tbody>
</table>
Bone marrow harvesting for transplantation; allogeneic
Bone marrow harvesting for transplantation; autologous
Hematopoietic progenitor cell (HPC); autologous transplantation
Fluid flow or fluid GF, 1 cc

**Coding Notes:**
- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- See the non-covered and prior authorization lists on the Company **Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website** for additional information.
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

**REFERENCES**


<table>
<thead>
<tr>
<th>DATE</th>
<th>REVISION SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/2023</td>
<td>Converted to new policy template.</td>
</tr>
</tbody>
</table>